Document is current
Any future updates will be listed below
-
Authors
Rochman, Mark https://orcid.org/0000-0002-0818-927X
Kellerman, Kendall
Jankowski, Michael P. https://orcid.org/0000-0002-4700-096X
Rothenberg, Marc E. https://orcid.org/0000-0001-9790-6332
- License Information
-
More Information
Article History
Accepted: 26 May 2025
First Online: 18 June 2025
Competing interests
: M.E.R. is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Allakos, Celldex, Uniquitybio, Santa Ana Bio, EnZen Therapeutics, Bristol Myers Squibb, Astra Zeneca, Pfizer, GlaxoSmithKline, Regeneron/Sanofi, Revolo Biotherapeutics and Guidepoint and has an equity interest in the first nine listed and royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust) and UpToDate. M.E.R. is an inventor on patents owned by Cincinnati Children’s Hospital. The other authors declare no competing interests.
